South & Central America Pharma ADMET Testing Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Testing Type (In Vivo ADMET Testing, In Vitro ADMET Testing, and In Silico ADMET Testing), Technology (Cell Culture, High Throughput, Molecul

South & Central America Pharma ADMET Testing Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Testing Type (In Vivo ADMET Testing, In Vitro ADMET Testing, and In Silico ADMET Testing), Technology (Cell Culture, High Throughput, Molecular Imaging, and OMICS Technology), and Application (Systemic Toxicity, Renal Toxicity, Hepatotoxicity, Neurotoxicity, and Others) 

The pharma ADMET testing market in South & Central America is expected to grow from US$ 386.47 million in 2022 to US$ 670.52 million by 2028. It is estimated to grow at a CAGR of 9.6% from 2022 to 2028.
Companies in the pharmaceuticals and biotechnology industries focus on the expansion of their research & development capabilities and drug manufacturing capacity. Rapid developments in computational software and the introduction of novel field technologies are estimated to raise the efficiency of drug development during the forecast period. For instance, toxicity, cytochrome p450 induction, and in vitro metabolism assays, among others, are being incorporated into a single assay on liver hepatocytes.
Similarly, 3D cell culture models with multiple tissue cell types are emerging as promising systems. Moreover, microfluidic organ-on-a-chip approaches, such as those commercialized by Emulate, are becoming more mainstream for predictive ADMET studies. ADMET Predictor by Simulations Plus, Inc., ADME/Tox by Sigma-Aldrich, LLC., PhysChem and ADME-Tox Prediction by ACD/Labs, PK/PD Database for Pharmacokinetic Properties by the Laboratory of Computational and Medicinal Chemistry, etc., are several tools developed for predicting toxicity related to ADME. Artificial intelligence (AI) may be used to simulate the ADME of drugs, determine if a therapeutic molecule will be effective in humans, and predict safety concerns.
During post-COVID recovery, the current popularity and concurrent emergence of AI and machine learning (ML) are likely to have a substantial impact on drug design and development. These technologies have decreased the need for human intervention and raised the quality of life of people as they can be implemented in designing superior-quality healthcare goods. With the help of specialized molecular modeling techniques, such as in-silico simulation, pharmacophore modeling, molecular dynamics, virtual screening, and molecular docking, AI&ML-driven rational drug design seeks to explain the unforeseen bioactivity of natural products most perfectly in a limited timeframe. Additionally, it describes the molecular interaction of drugs and their targets to create more effective drug leads. In January 2022, Charles River Laboratories and Valo Health, LLC, a technology firm leveraging human-centric data and AL-based computing, established a multi-year strategic collaboration to change the drug research & development process. A new revolutionary, AI-enabled drug discovery and development platform will be made available through this partnership by using Charles River's discovery optimization capabilities—including medicinal chemistry, ADME, biology, and pharmacology—and Valo's Opal Platform for small molecule development, which utilizes a closed-loop in a silico-experimental platform that rapidly iterates using program data to identify novel compounds. Thus, ADME testing based on automation, AI, and ML, among other technologies, is becoming an important part of the digital health boom, which is providing significant growth opportunities for the pharma ADMET testing market.
South & Central America Pharma ADMET Testing Market Revenue and Forecast to 2028 (US$ Million)

South & Central America Pharma ADMET Testing Market Segmentation

The South & Central America pharma ADMET testing market is segmented by testing type, technology, application, and country. Based on testing type, the South & Central America pharma ADMET testing market is segmented into in vivo ADMET testing, in vitro ADMET testing, and in silico ADMET testing. The in vivo ADMET testing segment dominated the market in 2022. Based on technology, the South & Central America pharma ADMET testing market is segmented into cell culture, high throughput, molecular imaging, and OMICS technology. The cell culture segment dominated the market in 2022. Based on application, the South & Central America pharma ADMET testing market is segmented into systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and others. The systemic toxicity segment dominated the market in 2022. Based on country, the South & Central America pharma ADMET testing market is segmented into Brazil, Argentina, and the rest of South & Central America. Further, Brazil dominated the market in 2022.
Some key players dominating the South & Central America pharma ADMET testing market are Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; Biovia (Dassault Systèmes); Charles River Laboratories; IQVIA Inc.; MERCK KGaA; and Promega Corporation.

Reasons to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the South & Central America pharma ADMET testing market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the South & Central America pharma ADMET testing market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the pharma ADMET testing market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution